Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May 2025 are set out below:<...
Home / Search Results
Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.
By Naomi Pearce, Chantal Savage, Nathan Kan | May 21, 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May 2025 are set out below:<...
By Bioblast Editor | May 21, 2025
On 15 May 2025, Regeneron announced that a jury of the US District Court for the District of Delaware found that Amgen had breached antitrust and tort laws by using cross-therapeutic bundling rebates, involving its anti-inflammatory drugs Enbrel® (etanercept) and Otezla® (a...
By Bioblast Editor | May 16, 2025
On 16 May 2025, Bristol Myers Squibb announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo® for the treatment of resectable non-small cell lung cancer (N...
By Bioblast Editor | May 15, 2025
On 15 May 2025, Regeneron announced that a jury of the US District Court for the District of Delaware found that Amgen had breached antitrust and tort laws by using cross-therapeutic bundling rebates, involving its anti-inflammatory drugs Enbrel® (etanercept) and Otezla® (a...
By Bioblast Editor | May 14, 2025
On 14 May 2025, Sanofi announced that Singapore’s Health Sciences Authority (HSA) has approved Dupixent® (dupilumab) for adults as an add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils who are...
By Naomi Pearce, Chantal Savage, Nathan Kan | May 13, 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May 2025 are set out below:
By Bioblast Editor | May 12, 2025
On 12 May 2025, the Canadian Federal Court published a decision (issued on 28 April 2025 on a confidential basis) granting Alexion an injunction preventing the Canadian launch of Amgen’s Bkemv®, biosimilar to Alexion’s Soliris® (eculizumab), until 15 March 2027. The decisi...
By Pearce IP | May 12, 2025
Pearce IP’s Founder and CEO Naomi Pearce is a finalist in two categories of the 2025 Lawyers Weekly Partner of the Year Awards:
Senior Partner of the Year – 15 Years or More<...
By Bioblast Editor | May 09, 2025
On 9 May 2025, New Zealand’s drug funding body, Pharmac, announced that it will be widening access to treatments for melanoma from 1 June 2025, including funding MSD’s Keytruda® (pembrolizumab) for resectable stage IIIB to stage IV melanoma, subject to eligibility criteria....
By Bioblast Editor | May 09, 2025
On 9 May 2025, Bayer announced that it has submitted a marketing authorisation application to the Ministry of Health, Labour and Welfare in Japan for Eylea™/aflibercept 8mg for treating patients with macular oedema following retinal vein occlusion (RVO).
This comes a...
SUBSCRIBE TO PEARCE IP